Granules India arm gets USFDA nod for Gout flares drug Colchicine

Colchicine Capsules are indicated for prophylaxis of gout flares in adults. Gout flares refer to sudden and intense episodes of pain, swelling, redness, and warmth in the joints, typically caused by the buildup of uric acid crystals. These flares often occur in the big toe but can also affect other joints such as the ankles, knees, elbows, wrists, and fingers.

Granules now have a total of 64 ANDA approvals from the US FDA (63 Final approvals and 1 tentative approvals). The current annual U.S. market for Colchicine Capsules is approximately $55 Million, according to MAT Feb 2024, IQVIA/IMS Health.

Read also: Granules India bags USFDA nod for Pantoprazole Sodium Delayed Release Tablets

Granules India Limited, incorporated in 1991 is a vertically integrated Indian pharmaceutical company headquartered in Hyderabad. The Company is among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs). Its products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, U.S. and U.K. The Company has 7 manufacturing facilities out of which 6 are located in India and 1 in USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC and HALAL.

Read also: Granules India subsidiary bags USFDA nod for Sildenafil for Oral Suspension